Topical Drug Delivery to the Posterior Segment of the Eye: Addressing the Challenge of Preclinical to Clinical Translation
Year: 2018
Type: article
Abstract: Topical delivery of therapeutics to the posterior segment of the eye remains the "holy grail" of ocular drug delivery. As an example, anti-vascular endothelial growth factor biologics, such as ranibizumab, aflibercept, and bevacizumab, are delivered by intravitreal injection to treat neovascular age-related macular degeneration and, although these drugs have revolutionized treatment of the disease, less invasive alternatives to intravitreal injection are desired. Multiple reports in the literature have demonstrated topical delivery of both small and large molecules to the back of the eye in small animal models. Despite this progress, successful translation to larger species, and ultimately humans, has yet to be demonstrated. Selection of animal models with relevant ocular anatomy and physiology, along with appropriate experimental design, is critical to enable more relevant feasibility assessments and increased probability of successful translation.
Source: Pharmaceutical Research
Authors: Gerard A. Rodrigues, David Lutz, Jie Shen, Xiaoda Yuan, Hong Shen, James Cunningham, Hongwen M. Rivers
Institution: Allergan (United States)
Language: English
Subfield: Pharmaceutical Science
Domain: Life Sciences
Keywords: topical drug delivery, posterior segment of the eye, ocular drug delivery, preclinical to clinical translation, ranibizumab, aflibercept, bevacizumab, neovascular age-related macular degeneration, intravitreal injection alternatives, animal model selection, small animal models, feasibility assessment
Open Access status: hybrid
Estimated APC paid: $4,690
OpenAlex ID: W2899208802
